<DOC>
	<DOCNO>NCT00108394</DOCNO>
	<brief_summary>The purpose study demonstrate whether pamidronate preserve increase bone mass patient adynamic bone disease , cause low bone turnover .</brief_summary>
	<brief_title>Osteopenia Renal Osteodystrophy : Evaluation Management</brief_title>
	<detailed_description>Detailed Summary : Bone disease well-recognized complication renal disease 100 year . Until advent dialysis , however , another many dreadful complication fatal disease . Almost since onset dialysis , however , bone disease calcium metabolism present major difficulty patient physician . Recently report dialysis patient 8-fold increase hip fracture rate , compare normal population . In young dialysis patient ( age 30-50 year ) risk increase nearly 100 fold . We also note similar even high incidence fracture transplant population . Low bone mass find dialysis patient investigator , find general population predispose fracture . In dialysis population , bone histologic study do u others report adynamic ( low turnover ) lesion half dialysis population . This lesion similar see osteoporosis . Thus , dialysis patient , like osteoporotics , low bone mass , low bone turnover , high fracture rate . In osteoporotic patient , various bisphosphonates show inhibit bone resorption , increase bone mass decrease fracture rate . The bisphosphonate approve use patient renal failure pamidronate . This agent use extensively general population must give intravenously . This , together fact pamidronate bone half-life 300 day , actually make drug strong candidate treatment patient renal failure . In investigation propose use pamidronate patient renal failure prevent bone loss fracture . We monitor bone mass DEXA patient assess treatment response , ass bone histology select subject , collect data fracture population . Comparison : Subjects normal low parathyroid hormone ( PTH ) receive dose pamidronate compare similar subject receive placebo . Comparison group randomly assign assignment blind .</detailed_description>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<criteria>Dialysis dependent minimum 3 month Age great 18 year Low normal bone turnover define mean intact PTH â‰¤400 pg/ml minimum two value 6 month apart Informed consent Mean serum aluminum level &gt; 20 mcg/L 1 year prior consent Documented dementia Comorbidity survival &gt; 3 year unlikely Use steroid within 3 month consent Use bisphosphonates previous 2 year Use sex hormone ( testosterone estrogen ) within 3 month consent Mean calcium &lt; 9.0 mg/dL two month prior consent Peritoneal dialysis patient Body weight &lt; 45 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Uremia</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Bone Diseases , Metabolic</keyword>
	<keyword>adynamic bone disease</keyword>
	<keyword>low bone turnover</keyword>
</DOC>